Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 17/20 | 0.84 |
| ▸ | DCLK1 | O15075 | 16/20 | 0.84 |
| ▸ | MAPK7 | Q13164 | 14/20 | 0.84 |
| ▸ | BRD4 | O60885 | 6/20 | 0.84 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.78 |
| ▸ | TNK1 | Q13470 | 2/20 | 0.78 |
| ▸ | DCLK2 | Q8N568 | 2/20 | 0.78 |
| ▸ | PLK4 | O00444 | 1/20 | 0.78 |
| ▸ | PI4KA | P42356 | 1/20 | 0.78 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.78 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.78 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.78 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.78 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.78 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.78 |
| ▸ | GAK | O14976 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17721081 | 0.93 | LRRK2 (0.85) | LRRK2DCLK1MAPK7BRD4TNK2 | |
| SCHEMBL31092831 | 0.92 | LRRK2 (1.00) | LRRK2DCLK1MAPK7BRD4TNK2 | |
| SCHEMBL20094504 | 0.92 | LRRK2 (1.00) | LRRK2DCLK1MAPK7BRD4TNK2 | |
| SCHEMBL618577 | 0.91 | LRRK2 (1.00) | LRRK2DCLK1MAPK7BRD4TNK2 | |
| SCHEMBL29372331 | 0.88 | LRRK2 (1.00) | LRRK2DCLK1MAPK7BRD4TNK2 | |
| SCHEMBL29356878 | 0.88 | LRRK2 (1.00) | LRRK2DCLK1MAPK7BRD4TNK2 | |
| SCHEMBL619295 | 0.88 | LRRK2 (1.00) | LRRK2DCLK1MAPK7BRD4TNK2 | |
| SCHEMBL617766 | 0.85 | MAPK7 (1.00) | LRRK2DCLK1MAPK7BRD4TNK2 | |
| SCHEMBL617027 | 0.85 | LRRK2 (1.00) | LRRK2DCLK1MAPK7BRD4TNK2 | |
| SCHEMBL17721080 | 0.84 | LRRK2 (0.86) | LRRK2DCLK1MAPK7BRD4TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | claimed |
| EP-3528814-B1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | DANA FARBER CANCER INST INC (US) | 2024-08-14 | — | — | EP | disclosed |
| US-11028089-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11028089-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3828185-A2 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| US-10570154-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190315753-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190315753-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | BROWN DENNIS M (US) | 2019-08-20 | — | — | US | disclosed |
| WO-2018075608-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| US-9464091-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-05 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, BRSK1, TAOK3 | LRRK2 364/4885DCLK1 480/4885MAPK7 263/4885 |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | NEK9, NEK7, NEK3 | LRRK2 1497/4885DCLK1 1124/4885MAPK7 295/4885 |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | LRRK2 340/4885DCLK1 453/4885MAPK7 253/4885 |
| US-10570154-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | BRSK2, STK3, BRSK1 | LRRK2 340/4885DCLK1 453/4885MAPK7 253/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | LRRK2 1497/4885DCLK1 1124/4885MAPK7 295/4885 |
| US-20190315753-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | CAMK1, CAMKK2, DCLK2 | LRRK2 162/4885DCLK1 7/4885MAPK7 589/4885 |
| US-11028089-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders | CAMK1, CAMKK2, DCLK2 | LRRK2 162/4885DCLK1 7/4885MAPK7 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.